Съгласно член 33, параграф 4 от Директива 2001/ 82/ ЕО и поправките към него, въпросът е отнесен към Комитета по лекарствените продукти за ветеринарна употреба (CVMP).
The reason for this was that the national competent authority of Germany considered that this veterinary medicinal product could present a potential serious risk to animal health on the grounds that the efficacy has not been sufficiently substantiated in the dossier.